OncoMatch/Clinical Trials/NCT07086105
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
Is NCT07086105 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Adze1.C for metastatic melanoma.
Treatment: Adze1.C — This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage IIIB, IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment options
Refractory to, or unsuitable for, standard treatment options as determined by the investigator.
Cannot have received: adenovirus therapy
Prior treatment with adenovirus therapy.
Cannot have received: oncolytic virus treatment
Exception: within 2 months of Screening
Prior oncolytic virus treatment within 2 months of Screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify